1
|
Adams DF, Watkins MS, Durette L, Laliberté J, Goulet F, Debien E, Frazier KS, Mellal N, Chen L, Shi W, Thomas R, Hu E. Carcinogenicity Assessment of Daprodustat (GSK1278863), a Hypoxia-Inducible Factor (HIF)-Prolyl Hydroxylase Inhibitor. Toxicol Pathol 2019; 48:362-378. [PMID: 31640478 DOI: 10.1177/0192623319880445] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
Daprodustat (GSK1278863) is a hypoxia-inducible factor (HIF)-prolyl hydroxylase (PHD) inhibitor in development for treatment of anemia of chronic kidney disease. Daprodustat's biological activity simulates components of the natural response to hypoxia; inhibition of PHDs results in HIF stabilization and modulation of HIF-controlled gene products, including erythropoietin. The carcinogenic potential of daprodustat was evaluated in 2-year carcinogenicity studies in Sprague-Dawley rats and CD-1 mice, where once-daily doses were administered. The mouse study also included evaluation of daprodustat's 3 major circulating human metabolites. There were no neoplastic findings that were considered treatment related in either study. Exaggerated pharmacology resulted in significantly increased red cell mass and subsequent multiorgan congestion and secondary non-neoplastic effects in both species, similar to those observed in chronic toxicity studies. In rats, these included aortic thrombosis and an exacerbation of spontaneous rodent cardiomyopathy, which contributed to a statistically significant decrease in survival in high-dose males (group terminated in week 94). Survival was not impacted in mice at any dose. Systemic exposures (area under the plasma concentration-time curve) to daprodustat at the high doses in rats and mice exceed predicted maximal human clinical exposure by ≥143-fold. These results suggest that daprodustat and metabolites do not pose a carcinogenic risk at clinical doses.
Collapse
Affiliation(s)
| | | | - Luc Durette
- Charles River Laboratories, Sherbrooke, Quebec, Canada
| | | | - Félix Goulet
- Charles River Laboratories, Senneville, Quebec, Canada
| | - Elaine Debien
- Charles River Laboratories, Sherbrooke, Quebec, Canada
| | | | - Nacéra Mellal
- Charles River Laboratories, Senneville, Quebec, Canada
| | | | - Wei Shi
- GlaxoSmithKline R&D, Collegeville, PA, USA
| | | | - Erding Hu
- GlaxoSmithKline R&D, Collegeville, PA, USA
| |
Collapse
|
2
|
Morton D, Sistare FD, Nambiar PR, Turner OC, Radi Z, Bower N. Regulatory Forum Commentary. Toxicol Pathol 2013; 42:799-806. [DOI: 10.1177/0192623313502130] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
International regulatory and pharmaceutical industry scientists are discussing revision of the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) S1 guidance on rodent carcinogenicity assessment of small molecule pharmaceuticals. A weight-of-evidence approach is proposed to determine the need for rodent carcinogenicity studies. For compounds with high human cancer risk, the product may be labeled appropriately without conducting rodent carcinogenicity studies. For compounds with minimal cancer risk, only a 6-month transgenic mouse study (rasH2 mouse or p53+/− mouse) or a 2-year mouse study would be needed. If rodent carcinogenicity testing may add significant value to cancer risk assessment, a 2-year rat study and either a 6-month transgenic mouse or a 2-year mouse study is appropriate. In many cases, therefore, one rodent carcinogenicity study could be sufficient. The rasH2 model predicts neoplastic findings relevant to human cancer risk assessment as well as 2-year rodent models, produces fewer irrelevant neoplastic outcomes, and often will be preferable to a 2-year rodent study. Before revising ICH S1 guidance, a prospective evaluation will be conducted to test the proposed weight-of-evidence approach. This evaluation offers an opportunity for a secondary analysis comparing the value of alternative mouse models and 2-year rodent studies in the proposed ICH S1 weight-of-evidence approach for human cancer risk assessment.
Collapse
Affiliation(s)
| | | | | | - Oliver C. Turner
- Novartis Pharmaceutical Corporation, East Hanover, New Jersey, USA
| | - Zaher Radi
- Pfizer, Inc., Cambridge, Massachusetts, USA
| | - Nancy Bower
- Eisai, Inc., Woodcliff Lake, New Jersey, USA
| |
Collapse
|